[{"id":"17a373bf-e674-4aa0-a914-22e6aff84f1c","acronym":"CIRCALL","url":"https://clinicaltrials.gov/study/NCT07483476","created_at":"2026-03-28T01:37:46.104Z","updated_at":"2026-03-28T01:37:46.104Z","phase":"","brief_title":"Study of Cell-free DNA in Children and Adolescents With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT07483476 - CIRCALL","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" ABL1 • KMT2A","pipe":" | ","alterations":" KMT2A rearrangement","tags":["ABL1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 205","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 07/01/2029","primary_completion_date":" 07/01/2029","study_txt":" Completion: 04/01/2034","study_completion_date":" 04/01/2034","last_update_posted":"2026-03-19"},{"id":"a7c4f9e4-84af-4d2b-9a47-edc69ca3a38e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07476729","created_at":"2026-03-28T01:40:41.936Z","updated_at":"2026-03-28T01:40:41.936Z","phase":"Phase 3","brief_title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","source_id_and_acronym":"NCT07476729","lead_sponsor":"Charite University, Berlin, Germany","biomarkers":" CD22","pipe":" | ","alterations":" CD19 positive • CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 03/31/2033","primary_completion_date":" 03/31/2033","study_txt":" Completion: 03/31/2033","study_completion_date":" 03/31/2033","last_update_posted":"2026-03-17"},{"id":"29314cf0-3dae-48bb-bacc-9547b377d15c","acronym":"","url":"https://clinicaltrials.gov/study/NCT07471789","created_at":"2026-03-28T01:43:57.744Z","updated_at":"2026-03-28T01:43:57.744Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).","source_id_and_acronym":"NCT07471789","lead_sponsor":"Gyala Therapeutics","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 02/04/2026","start_date":" 02/04/2026","primary_txt":" Primary completion: 05/31/2029","primary_completion_date":" 05/31/2029","study_txt":" Completion: 02/04/2031","study_completion_date":" 02/04/2031","last_update_posted":"2026-03-13"},{"id":"2f59ed54-b06e-4d43-9212-6877b8a1fbe8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07470073","created_at":"2026-03-28T01:44:17.302Z","updated_at":"2026-03-28T01:44:17.302Z","phase":"Phase 1","brief_title":"A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults","source_id_and_acronym":"NCT07470073","lead_sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2026-03-13"},{"id":"842583e2-8e92-49fc-94d6-2f73865d1b14","acronym":"","url":"https://clinicaltrials.gov/study/NCT07203352","created_at":"2025-10-04T08:00:11.817Z","updated_at":"2025-10-04T08:00:11.817Z","phase":"Phase 3","brief_title":"Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL","source_id_and_acronym":"NCT07203352","lead_sponsor":"Nanfang Hospital, Southern Medical University","biomarkers":" ABL2","pipe":"","alterations":" ","tags":["ABL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib"],"overall_status":"Recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-10-02"},{"id":"29889af3-ae43-4e06-bdfc-acec22c139fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT07198867","created_at":"2025-10-04T08:02:56.736Z","updated_at":"2025-10-04T08:02:56.736Z","phase":"Phase 1","brief_title":"A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT07198867","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/30/2025","start_date":" 09/30/2025","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-09-30"},{"id":"8551971c-dc39-40b0-a802-ab21b9ec4738","acronym":"","url":"https://clinicaltrials.gov/study/NCT07188740","created_at":"2025-09-27T08:44:07.719Z","updated_at":"2025-09-27T08:44:07.719Z","phase":"Phase 1","brief_title":"Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia","source_id_and_acronym":"NCT07188740","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" DNMT3A","pipe":"","alterations":" ","tags":["DNMT3A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/30/2025","start_date":" 10/30/2025","primary_txt":" Primary completion: 08/30/2027","primary_completion_date":" 08/30/2027","study_txt":" Completion: 08/30/2029","study_completion_date":" 08/30/2029","last_update_posted":"2025-09-23"},{"id":"1ab27b74-e0f4-4cec-8b70-3ecfc4fb824b","acronym":"Ven-BUCY","url":"https://clinicaltrials.gov/study/NCT07183878","created_at":"2025-09-27T08:46:54.624Z","updated_at":"2025-09-27T08:46:54.624Z","phase":"","brief_title":"Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)","source_id_and_acronym":"NCT07183878 - Ven-BUCY","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 08/20/2025","start_date":" 08/20/2025","primary_txt":" Primary completion: 08/20/2027","primary_completion_date":" 08/20/2027","study_txt":" Completion: 08/20/2028","study_completion_date":" 08/20/2028","last_update_posted":"2025-09-19"},{"id":"5dbd5ae2-c64a-4324-a92e-acf2900c0634","acronym":"CHANCE","url":"https://clinicaltrials.gov/study/NCT07172204","created_at":"2025-09-20T07:07:45.699Z","updated_at":"2025-09-20T07:07:45.699Z","phase":"Phase 2","brief_title":"Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML","source_id_and_acronym":"NCT07172204 - CHANCE","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 08/15/2025","start_date":" 08/15/2025","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 07/31/2029","study_completion_date":" 07/31/2029","last_update_posted":"2025-09-15"},{"id":"b6808cda-ab2a-4b3d-8cc3-0eab5b5b4415","acronym":"","url":"https://clinicaltrials.gov/study/NCT07157579","created_at":"2025-09-06T13:39:27.500Z","updated_at":"2025-09-06T13:39:27.500Z","phase":"","brief_title":"Notch 1 Mutation in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patient","source_id_and_acronym":"NCT07157579","lead_sponsor":"Sohag University","biomarkers":" BCL2 • NOTCH1","pipe":"","alterations":" ","tags":["BCL2 • NOTCH1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2025-09-05"},{"id":"8ecfd71e-09dc-439f-af05-bbb7a6382e68","acronym":"","url":"https://clinicaltrials.gov/study/NCT07130695","created_at":"2025-08-23T13:32:09.751Z","updated_at":"2025-08-23T13:32:09.751Z","phase":"Phase 1","brief_title":"Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation","source_id_and_acronym":"NCT07130695","lead_sponsor":"Virginia Commonwealth University","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rezlidhia (olutasidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 10/31/2025","start_date":" 10/31/2025","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2029","study_completion_date":" 10/31/2029","last_update_posted":"2025-08-19"},{"id":"cbd75b78-349b-4631-8a47-5cdf0f95df72","acronym":"","url":"https://clinicaltrials.gov/study/NCT07113132","created_at":"2025-08-09T14:21:21.716Z","updated_at":"2025-08-09T14:21:21.716Z","phase":"","brief_title":"Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia","source_id_and_acronym":"NCT07113132","lead_sponsor":"Safaa Ali","biomarkers":" SF3B1","pipe":"","alterations":" ","tags":["SF3B1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-08-08"},{"id":"4bb42519-747d-45f0-98ad-774255094bb0","acronym":"","url":"https://clinicaltrials.gov/study/NCT07109518","created_at":"2025-08-09T14:25:49.588Z","updated_at":"2025-08-09T14:25:49.588Z","phase":"Phase 1","brief_title":"uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies","source_id_and_acronym":"NCT07109518","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/28/2025","start_date":" 06/28/2025","primary_txt":" Primary completion: 06/28/2028","primary_completion_date":" 06/28/2028","study_txt":" Completion: 06/28/2030","study_completion_date":" 06/28/2030","last_update_posted":"2025-08-07"},{"id":"f211649c-22e9-4730-af7a-e9c8ed08f4b3","acronym":"REBELLE","url":"https://clinicaltrials.gov/study/NCT07099443","created_at":"2025-08-02T14:01:04.437Z","updated_at":"2025-08-02T14:01:04.437Z","phase":"","brief_title":"Determinants of the Response to BTK Degraders (BTKd) in Double Refractory CLL","source_id_and_acronym":"NCT07099443 - REBELLE","lead_sponsor":"Nantes University Hospital","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 09/15/2025","primary_completion_date":" 09/15/2025","study_txt":" Completion: 09/15/2039","study_completion_date":" 09/15/2039","last_update_posted":"2025-08-01"},{"id":"17ec08d3-56ea-4c5d-ada4-f104db624c1e","acronym":"CMD63","url":"https://clinicaltrials.gov/study/NCT07078929","created_at":"2025-07-26T13:32:53.310Z","updated_at":"2025-07-26T13:32:53.310Z","phase":"Phase 1","brief_title":"Phase I Clinical Trial of CMD63 CAR T Cell in Children With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT07078929 - CMD63","lead_sponsor":"Chulalongkorn University","biomarkers":" IL7R","pipe":"","alterations":" ","tags":["IL7R"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2025-07-22"},{"id":"17c029cc-5449-4ba9-99f6-13ebaefd3227","acronym":"EVOLVE 1","url":"https://clinicaltrials.gov/study/NCT07075016","created_at":"2025-07-26T13:34:40.222Z","updated_at":"2025-07-26T13:34:40.222Z","phase":"Phase 3","brief_title":"Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy","source_id_and_acronym":"NCT07075016 - EVOLVE 1","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 227","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-07-20"},{"id":"78b1d8da-ee62-4e5e-a188-4a012d565c96","acronym":"","url":"https://clinicaltrials.gov/study/NCT06863402","created_at":"2025-07-19T13:20:16.362Z","updated_at":"2025-07-19T13:20:16.362Z","phase":"Phase 2","brief_title":"Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype","source_id_and_acronym":"NCT06863402","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • nemtabrutinib (MK-1026)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 04/01/2029","primary_completion_date":" 04/01/2029","study_txt":" Completion: 04/01/2030","study_completion_date":" 04/01/2030","last_update_posted":"2025-07-18"},{"id":"1788e76b-7d7b-4891-bdd0-dfbb58176132","acronym":"","url":"https://clinicaltrials.gov/study/NCT07046078","created_at":"2025-07-05T13:57:24.531Z","updated_at":"2025-07-05T13:57:24.531Z","phase":"Phase 2","brief_title":"Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer","source_id_and_acronym":"NCT07046078","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • fludarabine IV • Starasid (cytarabine ocfosfate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2025-07-02"},{"id":"f73113c5-10a0-4d17-963d-5c3a022450a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT07039877","created_at":"2025-06-28T13:39:04.007Z","updated_at":"2025-06-28T13:39:04.007Z","phase":"Phase 2","brief_title":"Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients","source_id_and_acronym":"NCT07039877","lead_sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • bortezomib • itraconazole"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 01/02/2025","start_date":" 01/02/2025","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-06-26"},{"id":"9fd3bca0-1c10-442b-a00f-722b814378c6","acronym":"CD33 CAR NK","url":"https://clinicaltrials.gov/study/NCT07026942","created_at":"2025-06-21T13:17:33.882Z","updated_at":"2025-06-21T13:17:33.882Z","phase":"Phase 1/2","brief_title":"Phase I/II Clinical Trial Evaluating the Safety and Efficacy of Universal Donor CD33 CAR Natural Killer Cells for Treatment of Myeloid Leukemia","source_id_and_acronym":"NCT07026942 - CD33 CAR NK","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2031","primary_completion_date":" 07/01/2031","study_txt":" Completion: 07/01/2037","study_completion_date":" 07/01/2037","last_update_posted":"2025-06-18"},{"id":"2698d9cc-7b84-4f76-aa1a-1e9120402516","acronym":"MAVRiC","url":"https://clinicaltrials.gov/study/NCT07024706","created_at":"2025-06-21T13:19:49.221Z","updated_at":"2025-06-21T13:19:49.221Z","phase":"Phase 2","brief_title":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab","source_id_and_acronym":"NCT07024706 - MAVRiC","lead_sponsor":"AstraZeneca","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/30/2025","start_date":" 09/30/2025","primary_txt":" Primary completion: 11/30/2032","primary_completion_date":" 11/30/2032","study_txt":" Completion: 11/30/2032","study_completion_date":" 11/30/2032","last_update_posted":"2025-06-17"},{"id":"27333119-b7fd-424a-9cb7-3d186e837736","acronym":"","url":"https://clinicaltrials.gov/study/NCT06965114","created_at":"2025-06-14T13:57:06.110Z","updated_at":"2025-06-14T13:57:06.110Z","phase":"Phase 1/2","brief_title":"Study for Patients With Hairy Cell Leukemia to Test the Targeted Agent Tovorafenib in Combination With Rituximab and Compare the Combination With Current Standard Treatment","source_id_and_acronym":"NCT06965114","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cladribine • Ojemda (tovorafenib) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 09/30/2025","start_date":" 09/30/2025","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-06-11"},{"id":"1d2cc1b3-1db7-4ec6-826d-f95392ccf5c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT07012447","created_at":"2025-06-14T13:57:18.760Z","updated_at":"2025-06-14T13:57:18.760Z","phase":"Phase 2","brief_title":"Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations","source_id_and_acronym":"NCT07012447","lead_sponsor":"yuejun Liu","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-06-10"},{"id":"7883fa9a-7075-4f79-91ca-579902335b6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07008872","created_at":"2025-06-07T14:17:33.977Z","updated_at":"2025-06-07T14:17:33.977Z","phase":"","brief_title":"CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia","source_id_and_acronym":"NCT07008872","lead_sponsor":"Qi deng","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2025-06-06"}]